As a result of the Covid-19 crisis, the digital health sector has experienced massive growth with the adoption of telehealth and telemedicine services. Dealmakers continue to be more cautious and selective, but buyers are looking to take advantage of opportunistic acquisitions. Private equity has record amounts of capital that needs to be deployed, but valuations and pricing are being severely affected by current market volatility.
It is becoming apparent that the pandemic will continue well into 2021, and with the Biden administration taking office in January, what will the healthcare deal environment look like moving forward? Will valuations and pricing continue to be affected? What businesses adjacent to telehealth and telemedicine are seeing increased attention from healthcare private equity investors? How do investors view the news of potential vaccine candidates and what do these announcements do to the market? This panel of dealmakers will share their perspective on the current state of private equity healthcare investing.
- Benjamin Daverman, Managing Director, GTCR
- Lenard Marcus, General Partner, Edison Partners
- Lisa Mazur, Partner, McDermott Will & Emery
- Jeff Rhodes, Partner, TPG Capital
- Peter Segall, Managing Director, Insight Partners